دورية أكاديمية
أعرض في EDS

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.

التفاصيل البيبلوغرافية
العنوان: Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study.
المؤلفون: Hensley KS; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands., Jongkees MJ; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands., Geers D; Department of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands., GeurtsvanKessel CH; Department of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands., Mueller YM; Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands., Dalm VASH; Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands.; Department of Internal Medicine, Division of Allergy & Clinical Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands., Papageorgiou G; Department of Biostatistics, Erasmus University Medical Centre, Rotterdam, Netherlands., Steggink H; Department of Internal Medicine and Infectious Diseases, OLVG Hospital, Amsterdam, Netherlands., Gorska A; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands., Bogers S; Department of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands., den Hollander JG; Department of Internal Medicine, Maasstad Hospital, Rotterdam, Netherlands., Bierman WFW; Department of Internal Medicine, Section Infectious Diseases, University of Groningen, Groningen, Netherlands., Gelinck LBS; Department of Internal Medicine and Infectious Diseases, Haaglanden Medical Centre, The Hague, Netherlands., Schippers EF; Department of Internal Medicine, Haga Teaching Hospital, The Hague, Netherlands.; Department of Infectious Diseases, Leiden University Medical Centre, Leiden Netherlands., Ammerlaan HSM; Department of Internal Medicine, Catharina Hospital, Eindhoven, Netherlands., van der Valk M; Department of Internal Medicine and Infectious Diseases, DC Klinieken, Amsterdam, Netherlands.; Department of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, Netherlands., van Vonderen MGA; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, Netherlands., Delsing CE; Department of Internal Medicine and Infectious Diseases, Medisch Spectrum Twente, Enschede, Netherlands., Gisolf EH; Department of Internal Medicine and Infectious Diseases, Rijnstate Hospital, Arnhem, Netherlands., Bruns AHW; Department of Internal Medicine and Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands., Lauw FN; Department of Internal Medicine and Infectious Diseases, Medical Centre Jan van Goyen, Amsterdam, Netherlands., Berrevoets MAH; Department of Internal Medicine, Elisabeth-Tweesteden Hospital, Tilburg, Netherlands., Sigaloff KCE; Department of Internal Medicine, Division of Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centre, Vrije Universiteit Amsterdam, Amsterdam, Netherlands., Soetekouw R; Department of Internal Medicine and Infectious Diseases, Spaarne Gasthuis, Haarlem, Netherlands., Branger J; Department of Internal Medicine, Flevo Hospital, Almere, Netherlands., de Mast Q; Department of Internal Medicine, Radboud Centre for Infectious Diseases, Radboud University Medical Centre, Nijmegen, Netherlands., Lammers AJJ; Department of Internal Medicine and Infectious Diseases, Isala Hospital, Zwolle, Netherlands., Lowe SH; Department of Internal Medicine and Infectious Diseases, Maastricht University Medical Centre, Maastricht, Netherlands., de Vries RD; Department of Viroscience, Erasmus University Medical Centre, Rotterdam, Netherlands., Katsikis PD; Department of Immunology, Erasmus University Medical Centre, Rotterdam, Netherlands., Rijnders BJA; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands., Brinkman K; Department of Internal Medicine and Infectious Diseases, OLVG Hospital, Amsterdam, Netherlands., Roukens AHE; Department of Infectious Diseases, Leiden University Medical Centre, Leiden Netherlands., Rokx C; Department of Internal Medicine, Section Infectious Diseases, and Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, Netherlands.
المصدر: PLoS medicine [PLoS Med] 2022 Oct 27; Vol. 19 (10), pp. e1003979. Date of Electronic Publication: 2022 Oct 27 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101231360 Publication Model: eCollection Cited Medium: Internet ISSN: 1549-1676 (Electronic) Linking ISSN: 15491277 NLM ISO Abbreviation: PLoS Med Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science, [2004]-
مواضيع طبية MeSH: COVID-19*/epidemiology , COVID-19*/prevention & control , COVID-19 Vaccines*/immunology , HIV Infections*/immunology, Adult ; Female ; Humans ; Male ; Middle Aged ; Ad26COVS1 ; Antibodies, Viral ; BNT162 Vaccine ; Immunogenicity, Vaccine ; Immunoglobulin G ; Netherlands/epidemiology ; Prospective Studies ; RNA, Messenger ; SARS-CoV-2 ; mRNA Vaccines
مستخلص: Background: Vaccines can be less immunogenic in people living with HIV (PLWH), but for SARS-CoV-2 vaccinations this is unknown. In this study we set out to investigate, for the vaccines currently approved in the Netherlands, the immunogenicity and reactogenicity of SARS-CoV-2 vaccinations in PLWH.
Methods and Findings: We conducted a prospective cohort study to examine the immunogenicity of BNT162b2, mRNA-1273, ChAdOx1-S, and Ad26.COV2.S vaccines in adult PLWH without prior COVID-19, and compared to HIV-negative controls. The primary endpoint was the anti-spike SARS-CoV-2 IgG response after mRNA vaccination. Secondary endpoints included the serological response after vector vaccination, anti-SARS-CoV-2 T-cell response, and reactogenicity. Between 14 February and 7 September 2021, 1,154 PLWH (median age 53 [IQR 44-60] years, 85.5% male) and 440 controls (median age 43 [IQR 33-53] years, 28.6% male) were included in the final analysis. Of the PLWH, 884 received BNT162b2, 100 received mRNA-1273, 150 received ChAdOx1-S, and 20 received Ad26.COV2.S. In the group of PLWH, 99% were on antiretroviral therapy, 97.7% were virally suppressed, and the median CD4+ T-cell count was 710 cells/μL (IQR 520-913). Of the controls, 247 received mRNA-1273, 94 received BNT162b2, 26 received ChAdOx1-S, and 73 received Ad26.COV2.S. After mRNA vaccination, geometric mean antibody concentration was 1,418 BAU/mL in PLWH (95% CI 1322-1523), and after adjustment for age, sex, and vaccine type, HIV status remained associated with a decreased response (0.607, 95% CI 0.508-0.725, p < 0.001). All controls receiving an mRNA vaccine had an adequate response, defined as >300 BAU/mL, whilst in PLWH this response rate was 93.6%. In PLWH vaccinated with mRNA-based vaccines, higher antibody responses were predicted by CD4+ T-cell count 250-500 cells/μL (2.845, 95% CI 1.876-4.314, p < 0.001) or >500 cells/μL (2.936, 95% CI 1.961-4.394, p < 0.001), whilst a viral load > 50 copies/mL was associated with a reduced response (0.454, 95% CI 0.286-0.720, p = 0.001). Increased IFN-γ, CD4+ T-cell, and CD8+ T-cell responses were observed after stimulation with SARS-CoV-2 spike peptides in ELISpot and activation-induced marker assays, comparable to controls. Reactogenicity was generally mild, without vaccine-related serious adverse events. Due to the control of vaccine provision by the Dutch National Institute for Public Health and the Environment, there were some differences between vaccine groups in the age, sex, and CD4+ T-cell counts of recipients.
Conclusions: After vaccination with BNT162b2 or mRNA-1273, anti-spike SARS-CoV-2 antibody levels were reduced in PLWH compared to HIV-negative controls. To reach and maintain the same serological responses as HIV-negative controls, additional vaccinations are probably required.
Trial Registration: The trial was registered in the Netherlands Trial Register (NL9214). https://www.trialregister.nl/trial/9214.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: All authors have completed the ICMJE disclosure form and declare no competing interests exist directly related to the submitted work Conflicts of interest outside the submitted work CR has received research grants from ViiV, Gilead, ZonMW, AIDSfonds, Erasmus MC, and Health~Holland and honorariums for advisory boards from Gilead and ViiV; WFWB declares reimbursement for participation of patient in trial by GSK to institution. DG and RDdV are supported by the Health~Holland grant EMCLHS20017 co-funded by the PPP Allowance made available by the Health~Holland, Top Sector Life Sciences & Health, to stimulate public–private partnerships. RDdV is listed as inventor of the fusion inhibitory lipopeptide [SARSHRC-PEG4]2-chol on a provisional patent application. VASHD has received research grants from ZonMw, Horizon 2020 – Marie Curie-Sklodowska, Takeda and payments for lectures and advisory boards from Takeda, CSL Behring, Pharming and GSK. KCES received honorariums for advisory boards from Gilead and ViiV. BJAR declares research grants from Gilead and MSD and honorary for advisory boards for Astra Zeneca, Roche, Gilead, F2G all outside the context of this work. RvM received consultancies fees paid to their institution from ViiV; Gilead; MSD, received research grants paid to their institution from ViiV; Gilead All other authors declare hat no competing interests exist.
التعليقات: Erratum in: PLoS Med. 2023 Jan 6;20(1):e1004159. doi: 10.1371/journal.pmed.1004159. (PMID: 36608645)
References: Nature. 2021 Aug;596(7872):417-422. (PMID: 34192737)
Clin Infect Dis. 2022 Apr 9;74(7):1268-1270. (PMID: 34293114)
EClinicalMedicine. 2021 Aug;38:101018. (PMID: 34278286)
Sci Immunol. 2022 Mar 25;7(69):eabo2202. (PMID: 35113647)
Clin Microbiol Infect. 2021 Dec;27(12):1851-1855. (PMID: 34438069)
J Allergy Clin Immunol. 2022 Jun;149(6):1949-1957. (PMID: 35421449)
Science. 2022 Jan 07;375(6576):43-50. (PMID: 34812653)
AIDS. 2018 Jun 1;32(9):1085-1094. (PMID: 29424779)
Lancet HIV. 2021 Aug;8(8):e474-e485. (PMID: 34153264)
Front Immunol. 2019 Dec 18;10:2858. (PMID: 31921128)
Immun Inflamm Dis. 2018 Sep;6(3):392-401. (PMID: 29974672)
Lancet. 2021 Jan 9;397(10269):99-111. (PMID: 33306989)
Nat Commun. 2021 Jan 11;12(1):267. (PMID: 33431879)
J Intern Med. 2022 Apr;291(4):513-518. (PMID: 34841629)
Cochrane Database Syst Rev. 2014 Jan 23;(1):CD010929. (PMID: 24453061)
Lancet Oncol. 2021 Dec;22(12):1681-1691. (PMID: 34767759)
JAMA Netw Open. 2022 Jun 1;5(6):e2215934. (PMID: 35671054)
Clin Infect Dis. 2023 Feb 8;76(3):e522-e525. (PMID: 35793242)
N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609)
Lancet HIV. 2021 Jun;8(6):e334-e341. (PMID: 33933189)
N Engl J Med. 2022 Mar 10;386(10):951-963. (PMID: 35045226)
Lancet HIV. 2021 Nov;8(11):e661-e662. (PMID: 34655548)
Virulence. 2017 Jul 4;8(5):508-528. (PMID: 28276994)
Nature. 2022 Mar;603(7901):493-496. (PMID: 35102312)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
J Infect Dis. 2023 Mar 1;227(5):651-662. (PMID: 36402141)
Hum Vaccin Immunother. 2017 Jun 3;13(6):1-10. (PMID: 28267387)
N Engl J Med. 2022 Mar 3;386(9):847-860. (PMID: 35139271)
Lancet. 2021 Dec 19;396(10267):1979-1993. (PMID: 33220855)
J Clin Microbiol. 2021 Nov 18;59(12):e0138121. (PMID: 34524886)
Lancet Microbe. 2022 Jan;3(1):e52-e61. (PMID: 34806056)
J Infect Dis. 2023 Apr 12;227(7):838-849. (PMID: 35668700)
Nat Rev Immunol. 2022 Feb;22(2):75. (PMID: 35017722)
N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246)
Lancet HIV. 2021 Sep;8(9):e568-e580. (PMID: 34416193)
سلسلة جزيئية: NTR NL9214
المشرفين على المادة: JT2NS6183B (Ad26COVS1)
0 (Antibodies, Viral)
0 (BNT162 Vaccine)
0 (COVID-19 Vaccines)
0 (Immunoglobulin G)
0 (RNA, Messenger)
تواريخ الأحداث: Date Created: 20221027 Date Completed: 20221102 Latest Revision: 20240906
رمز التحديث: 20240906
مُعرف محوري في PubMed: PMC9612532
DOI: 10.1371/journal.pmed.1003979
PMID: 36301821
قاعدة البيانات: MEDLINE
الوصف
تدمد:1549-1676
DOI:10.1371/journal.pmed.1003979